9.12 Protocol Specific Research Support The University of Minnesota Cancer Center (UMCC) strongly supports the implementation of "investigatorinitiated" clinical trials. These trials test novel therapeutic agents developed at our institution, or innovative application of currently available therapeutic agents. Seventy-seven local, investigator-initiated clinical trials have been implemented during the current funding period, .and an additional 15 are in the final stages of development. These trials test a variety of approaches including hematopoietic cell transplantation, nontransplant immunotherapy, novel combinations of chemo-therapy, multimodality therapy, and pharmacotherapeutic monitoring. At the University of Minnesota Cancer Center, investigator-initiated clinical research efforts exist across a wide spectrum of disciplines including cancer prevention, screening, and many therapeutic modalities. However, senior cancer center leadership has identified non-transplant cell and immune-based cancer therapy as the area of highest scientific priority for focused, protocol-specific research support during the current and proposed funding periods. This strategy builds on the historic strength of our Transplant Biology and Therapy Program and collaborations with the Immunology Program. It is supported by the Clinical Trials Office and by the Translational Therapy Shared Resource. When fully implemented, this approach is intended to address both hematologic malignancies and a variety of solid tumors in children and adults. Cancer Center leadership has selected several non-transplant cell or immune-based cancer therapy initiative for proposed protocol specific research support. Criteria for selection include innovation, progress, involvement of more than one Cancer Center program, use of Shared Resources, potential for therapeutic application to solid tumor malignancies and need for clinical trial support. In the proposed funding period, ongoing selection of highest scientific priority clinical research will be made by the Clinical Research Leadership Team (CRL) composed of senior cancer center leadership with expertise in translational and clinicalresearch. Recommendations concerning clinical trials of highest scientific priority will be ratified by the Cancer Center Executive Advisory Committee.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA077598-15
Application #
8450013
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
15
Fiscal Year
2013
Total Cost
$109,279
Indirect Cost
$36,908
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Abbott, Kenneth L; Nyre, Erik T; Abrahante, Juan et al. (2015) The Candidate Cancer Gene Database: a database of cancer driver genes from forward genetic screens in mice. Nucleic Acids Res 43:D844-8
Yee, Douglas (2015) A tale of two receptors: insulin and insulin-like growth factor signaling in cancer. Clin Cancer Res 21:667-9
Daniel, A R; Gaviglio, A L; Knutson, T P et al. (2015) Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes. Oncogene 34:506-15
Upadhyaya, Pramod; Hecht, Stephen S (2015) Quantitative analysis of 3'-hydroxynorcotinine in human urine. Nicotine Tob Res 17:524-9
Patel, Yesha M; Stram, Daniel O; Wilkens, Lynne R et al. (2015) The contribution of common genetic variation to nicotine and cotinine glucuronidation in multiple ethnic/racial populations. Cancer Epidemiol Biomarkers Prev 24:119-27
Takahashi, Yutaka; Hui, Susanta K (2014) Fast, simple, and informative patient-specific dose verification method for intensity modulated total marrow irradiation with helical tomotherapy. Radiat Oncol 9:34
Cooley, Sarah; Weisdorf, Daniel J; Guethlein, Lisbeth A et al. (2014) Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia. J Immunol 192:4592-600
Chen, Liddy M; Ibrahim, Joseph G; Chu, Haitao (2014) Flexible stopping boundaries when changing primary endpoints after unblinded interim analyses. J Biopharm Stat 24:817-33
Landman, Sean R; Hwang, Tae Hyun; Silverstein, Kevin A T et al. (2014) SHEAR: sample heterogeneity estimation and assembly by reference. BMC Genomics 15:84
Gates, Leah A; Phillips, Martin B; Matter, Brock A et al. (2014) Comparative metabolism of furan in rodent and human cryopreserved hepatocytes. Drug Metab Dispos 42:1132-6

Showing the most recent 10 out of 319 publications